Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 14, 2023

BUY
$8.29 - $16.97 $280,425 - $574,044
33,827 New
33,827 $570,000
Q1 2022

May 16, 2022

SELL
$4.6 - $5.8 $399,684 - $503,950
-86,888 Closed
0 $0
Q3 2021

Nov 15, 2021

BUY
$6.7 - $11.54 $1,956 - $3,369
292 Added 0.34%
86,888 $671,000
Q2 2021

Aug 16, 2021

BUY
$11.66 - $24.23 $1.01 Million - $2.1 Million
86,596 New
86,596 $1.01 Million

Others Institutions Holding VECT

# of Institutions
1
Shares Held
510K
Call Options Held
0
Put Options Held
0

About VectivBio Holding AG


  • Ticker VECT
  • Exchange NASDAQ
  • Description
  • VectivBio Holding AG, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for treatments of severe rare conditions. It develops apraglutide, a long-acting synthetic peptide analog of glucagon-like peptide-2 that is in Phase III clinical trial for the treatment of patients with sho...
More about VECT
Track This Portfolio

Track Woodline Partners LP Portfolio

Follow Woodline Partners LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Woodline Partners LP, based on Form 13F filings with the SEC.

News

Stay updated on Woodline Partners LP with notifications on news.